In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...
Read MoreType of non Hodgkin’s lymphoma-Other-Small cell lymphocytic lymphoma Posts on Medivizor
Treating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone
In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to other lines of treatment....
Read MoreHow safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?
In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...
Read MoreComparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma
In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Some background The number of treatment options for CLL and SLL has increased in the last few years. For a long...
Read MoreComparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma
In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Some background The number of treatment options for CLL and SLL has increased in the last few years. For a long...
Read MoreCopanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.
In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...
Read MoreComparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas
In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...
Read MoreOutcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas
In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...
Read MoreHow effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?
In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...
Read MoreEvaluating an antibody therapy for recurrent or non-responding NHL
In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (LT) for recurrent or non-responding non-Hodgkin’s lymphoma (NHL). This study found that LT showed promising effectiveness, with manageable side effects. Some background Patients with NHL often receive strong treatment to kill cancer cells. 60 to 70%...
Read MoreIs R-CVP safer and more effective than R-CHOP for patients with painless NHL?
In a nutshell This study evaluated the safety and effectiveness of two different chemotherapy regimens for patients with indolent (painless) non-Hodgkin’s lymphoma (NHL). This study found that the R-CVP regimen was similarly effective and had fewer side effects compared to R-CHOP for these patients. Some background Chemoimmunotherapy is the...
Read MoreSurviving cancer – is there a greater risk of cardiovascular disease long-term?
In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read More